



Attorney Docket No. 55062 (7411)

TECH CENTER 1600/2900
JAN 31 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Edwin C. Gravereaux, et al.

U.S.S.N. 09/970,088

Art Unit: 1614


FILED: October 2, 2001

Examiner: Not yet assigned

FOR: USE OF LYMPHANGIOGENIC AGENTS TO TREAT LYMPHATIC DISORDERS

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, Postage prepaid, in an envelope addressed to BOX IDS, Assistant Commissioner for Patents, Washington, D.C. 20231 on January 8, 2002.

By: 
Patricia A. Barnes

**INFORMATION DISCLOSURE STATEMENT
(SUBMISSION AFTER FILING OF AN APPLICATION
BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE)**

BOX IDS
Assistant Commissioner for Patents and Trademarks
Washington, D.C. 20231

Date: January 8, 2002

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

Submission of the IDS should not be construed as an admission that any of the references contained therein is prior art. For example, references AH and AK have publication dates that are believed to be well after the priority date of the instant application. Submission of these references is solely intended to provide a better appreciation of the invention to the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II. COPIES

a. Submitted herewith is a legible copy of (i) each U.S and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.

III. CONCISE EXPLANATION OF THE RELEVANCE

(check at least one box)

a. Except as may be indicated below in (b), all of the patents, publications or other information are in the English language or were cited in an English language Search Report, a copy of which is attached hereto (concise explanation not required).

b. A concise explanation of the relevance of all patents, publications or other information listed that is not in the English language is as follows:

c. The following additional information is provided for the Examiner's consideration:

FEES

IV. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b) (check one box)

a. within three months of the filing date of a national application (37 C.F.R. § 1.97(b) (1)). No fee or certification is required.

b. within three months of the date of entry of the national stage as set forth in §1.491 in an international application (37 C.F.R. § 1.97(b) (2)). No fee or certification is required.

c. before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b) (3)). No fee or certification is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the certification under 37 C.F.R. § 1.97(e)below, or, if no certification has been made, charge our deposit account a fee in the amount of \$240.00 as required by 37 C.F.R. § 1.17(p).

V. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c);
(check one box)

before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c) (1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c) (2)).

a. No certification; therefore, a fee in the amount of \$180.00 is required by 37 C.F.R. § 1.17(p).
or
b. See the certification below. No fee is required.

VI. CERTIFICATION UNDER 37 C.F.R. § 1.97(e) (check only one box)

The undersigned hereby certifies that

a. each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or

b. no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

c. Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned certifies that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

Please charge Deposit Account No. 04-1105 in the amount of \$180.00 for the above-indicated fee. A triplicate copy of this paper is attached.

No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition, if necessary) and charge the appropriate fee to Deposit Account No. 04-1105.

Respectfully submitted,

Date: 8 Jan 02, 2002



Robert L. Buchanan (Reg. No. 40,927)
Dike, Bronstein, Roberts & Cushman
Intellectual Property Practice Group of
EDWARDS & ANGELL, LLP
P.O. Box 9169
Boston, MA 02209
Tel: (617) 439-4444
Fax: (617) 439-4170 / 7748

Customer No.: 21874

JAN 3 2002
TECH CENTER 1600/2800

RECEIVED

FORM PTO-1449		ATTY DOCKET NO.	SERIAL NO.
INFORMATION DISCLOSURE STATEMENT		55062 (71417)	09/970,088
		APPLICANT(S):	
		Edwin C. Gravereaux, et al.	
		FILING DATE:	ART UNIT:
		10/02/2001	1614

UNITED STATES PATENT DOCUMENTS

EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FIL. APPR

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN YES/NO
							See English Abstrac

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

	AA	Browse N.L. et al. The diagnosis and management of primary lymphedema. Vasc Surg 1986;3:181-184;
	AB	Szuba A. et al. Lymphedema: classification, diagnosis and therapy. Vascular Medicine 1998;3:145-156;
	AC	Dicken S.C. Ko et al. Effective treatment of lymphedema of the extremities. Arch Surg 1998;133:452-458;
	AD	Casley-Smith J.R. et al. A model of lymphoedema in the rabbit's ear. Th effect of benzopyrones. Chir Plast 1977;4:5-14;
	AE	Lee-Donaldson L. et al. Refinement of a rodent model of peripheral lymphedema. Lymphology 1999;32:111-117;
	AF	Kaipainen A. et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 1995;92:3566-3570;
	AG	Jeltsch M. et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 1997;276:1423-1425;

Examiner: Date:

TECH CENTER 600/2800
JAN 31 2002

RECEIVED

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT



ATTY DOCKET NO. 55062 (71417)	SERIAL NO. 09/970,088
APPLICANT(S): Edwin C. Gravereaux, et al.	
FILING DATE: 10/02/2001	ART UNIT: 1614

UNITED STATES PATENT DOCUMENTS

EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FIL. DATE I APPR

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN YES/NO

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

	AH	Makinen T. et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nature Med 2001;7:199-205;
	AI	Piller N.B. et al. Lymphoedema of the rabbit ear following partial and complete lymphatic blockade; its effects on fibrotic development, enzyme types and their activity levels. Br. J Exp Path 1978;59:319-326;
	AJ	Baumgartner I. et al. Constitutive expression of phVEGF ₁₆₅ after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998;97:1114-1123;
	AK	Schratzberger P. et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Inves 2001;107:1083-1092;
	AL	Witzenbichler B. et al. Vascular endothelial growth factor-C(VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am J Pathol 1998;153:381-394.
Examiner:		Date:

BOS2_184422.1